Treatment of a demyelinating disease of the central nervous system (CNS) with satralizumab

Abstract

The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.

Description

TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB

[0001] The present invention relates to a medicament or a pharmaceutical composition for treatment, or for reducing the risk of relapse, of a demyelinating disease of the central nervous system (CNS) that is characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, the composition comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof. The present invention also relates to a method of treatment, or of reducing the risk of relapse, of said demyelinating disease by administering an anti-IL-6 receptor antibody or antigen binding fragment thereof to a subject in need thereof.

[0002] Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune demyelinating disease of the CNS characterized by the presence of anti-myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in adults and children. MOG is a transmembrane protein expressed on oligodendrocytes and the outer layers of myelin sheath [NPL 19]. The disease is characterized by attacks of optic neuritis, transverse myelitis, brain or brainstem inflammation, or combinations thereof (NPL 1). A combination of a compatible clinical and radiologic phenotype and seropositivity for MOG-IgG is required to establish the diagnosis. In about 80% of adult patients, the disease is chronic, characterized by a relapsing course (NPL 2, NPL 3, and NPL 4). The proportion of adolescents with relapsing disease course is believed to be similar to adults (NPL 5 and NPL 6). MOGAD-associated disability is attack / relapse-driven, hence the importance of relapse prevention. There are no approved therapies for MOGAD, and consensus-based treatment guidelines are missing. MOGAD is worsened by several multiple sclerosis (MS) disease-modifying treatments, including interferon-beta (IFN-beta), glatiramer acetate, teriflunomide, dimethyl fumarate, cladribine, fingolimod, natalizumab, and alemtuzumab (NPL 7, NPL 8, NPL 9, and NPL 6). The current MOGAD treatment paradigm includes the use of corticosteroids with or without intravenous immunoglobulins (IVIg) or plasma exchange (PLEX) for acute treatment of attacks, and empirically selected conventional steroid-sparing immunosuppressant treatments (ISTs) and rituximab (RTX) for relapse prevention (NPL 10, NPL 9, NPL 11, NPL 12, and NPL 13). Most recent literature indicates that these medications, which are associated with numerous short and long-term adverse effects, are often only partially effective (NPL 9, NPL 14, NPL 15, and NPL 6). There continues to be a need for safe, provenly effective and convenient chronic treatments for MOGAD.

[0003] There is no approved treatment for MOGAD or for prevention of MOGAD relapses. ISTs used empirically off-label are often only partially effective, and many are associated with numerous short- and long-term adverse effects. Recently, elevated interleukin (IL)-6 levels in the cerebrospinal fluid (CSF) and serum have been reported in patients with MOGAD (NPL 16). There are some reports relating to the off-label use of tocilizumab, an anti-IL-6 receptor antibody in patients with MOGAD. However, the exact role of IL-6 in MOGAD is unclear. (NPL 17, NPL 18, and NPL 19).

[0004] Humanized antibodies like tocilizumab are first-generation antibody drugs. By improving first-generation antibody drugs, second-generation antibody drugs with improved efficacy, convenience, and cost are being developed (PTL 2 and PTL 3). Among the second-generation antibody drugs is satralizumab (SA237), which is a novel anti-IL-6 receptor antibody to which improvement technologies such as enhancement of antigen-binding ability, pharmacokinetics, and stability, and reduction of immunogenicity risk, have been applied (PTL 3 and PTL 4).

[0005] Satralizumab is a humanized anti-IL-6 receptor monoclonal antibody with pH-dependent antigen binding. It specifically targets the human IL-6 receptor (IL-6R) and suppresses IL-6 signaling by inhibiting the binding of IL-6 to membrane-bound IL-6R and soluble IL-6R. Satralizumab was constructed by modifying the amino acid sequence of tocilizumab to prolong its plasma half-life. Satralizumab also shows a decreased antibody molecule isoelectric point and stronger binding to FcRn compared to tocilizumab. Moreover, its Fc region has been modified to minimize the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic effector activity compared to tocilizumab. Prior-art literature information related to the invention of the present application is shown below.

[0006] [PTL 1] US2012 / 0039840 [PTL 2] WO2009 / 041621 [PTL 3] WO2010 / 035769 [PTL 4] WO2016 / 136933Non-Patent Literature

[0007] [NPL 1] Lopez-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 2018 Nov 1;75(11):1355-1363. [NPL 2] Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. [NPL 3] Hyun JW, Woodhall MR, Kim SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811-817. [NPL 4] Salama S, Pardo S, Levy M. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019;30:231-235. [NPL 5] Bruijstens AL, Breu M, Wendel E-M, et al. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody- associated disorders. Eur J Paediatr Neurol 2020b;29:32-40. [NPL 6] Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol. 2021;89(1):30-41. [NPL 7] Wildemann B, Jarius S, Schwarz A, et al. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology. 2017;89(2):207-209. [NPL 8] Wynford-Thomas R, Jacob A, et al. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280-1286. [NPL 9] Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111-e120. [NPL 10] Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572. [NPL 11] Chen JJ and Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47-54. [NPL 12] Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord. 2020;13:1756286420945135. [NPL 13] Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020a;267(12):3565-3577. [NPL 14] Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020b;44:102251. [NPL 15] Durozard P, Rico A, Boutiere C, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Ann Neurol. 2020;87(2):256-266. [NPL 16] Hofer LS, Mariotto S, Wurth S, et al. Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319848463. [NPL 17] Mult Scler Relat Disord. 2021 Feb;48:102696 [NPL 18] Mult Scler Relat Disord. 2020 Nov;46:102483 [NPL 19] Neurology. 2019 Apr 16;92(16):765-767

[0008] There is no approved treatment for MOGAD or for prevention of MOGAD relapses. ISTs used empirically off-label are often only partially effective, and many are associated with numerous short- and long-term adverse effects. There is a substantial unmet need for a treatment for MOGAD and also for prevention of MOGAD relapses that would subsequently improve the long-term prognosis in patients with MOGAD.

[0009] To solve the above-mentioned problem, the present inventors designed a phase III, randomized, double-blind (DB), placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as monotherapy or in addition (add-on) to baseline / background ISTs for MOGAD relapse prevention. It is expected that the phase III study herein will effectively treat MOGAD, prevent MOGAD attacks / relapses, and reduce the risk of MOGAD attacks / relapses.

[0010] The present disclosure includes but not limited to the embodiments as exemplarily described below. [A1.1] A medicament for treating a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, or for reducing risk of relapse in a relapsing demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody, in a subject who is anti-MOG antibody-positive, comprising an IL-6 inhibitor as an active ingredient. [A1.2] The medicament of A1.1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof. [A1.3] The medicament of A1.1 or A1.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof. [A1.4] The medicament of any one of A1.1-A1.3, wherein the IL-6 inhibitor is a humanized antibody. [A1.5] The medicament of any one of A1.1-A1.4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. [A1.6] The medicament of A1.5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2. [A1.7] The medicament of A1.5 or A1.6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4. [A1.8] The medicament of any one of A1.5-A1.7, wherein the IL-6 inhibitor is satralizumab. [A1.9] The medicament of any one of A1.1-A1.8, for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [A1.10] The medicament of any one of A1.1-A1.9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS). [A1.11] The medicament of any one of A1.1-A1.10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis. [A1.12] The medicament of any one of A1.1-A1.11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). [A1.13] The medicament of A1.12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [A1.14] The medicament of any one of A1.1-A1.13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [A1.15] The medicament of any one of A1.1-A1.14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative. [A1.16] The medicament of any one of A1.1-A1.15, wherein the subject is aged 12 years or older. [A1.17] The medicament of any one of A1.1-A1.16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy. [A1.18] The medicament of any one of A1.1-A1.16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS. [A1.19] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration. [A1.20] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [A1.21] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [A1.22] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [A1.23] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [A1.24] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [A1.25] The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [A1.26] The medicament of any one of A1.5-A1.25, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously. [A1.27] The medicament of any one of A1.5-A1.26, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [A1.28] The medicament of any one of A1.1-A1.27, which is characterized in that the medicament is used in combination with an immunosuppressive therapy (IST). [A1.29] The medicament of A1.28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF), and oral corticosteroid (OCS). [A1.30] The medicament of A1.29, wherein the immunosuppressive agent comprises prednisone or prednisolone. [A1.31] The medicament of any one of A1.1-A1.30, which delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [A1.32] The medicament of A1.31, which reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations. [A1.33] The medicament of any one of A1.1-A1.32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score, or MOG-IgG titers. [A2.1] A pharmaceutical composition for treating a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody or for reducing risk of relapse in a relapsing demyelinating disease of CNS characterized by the presence of an anti-MOG antibody in a subject who is anti-MOG antibody-positive, comprising an IL-6 inhibitor as an active ingredient. [A2.2] The pharmaceutical composition of A2.1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof. [A2.3] The pharmaceutical composition of A2.1 or A2.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof. [A2.4] The pharmaceutical composition of any one of A2.1-A2.3, wherein the IL-6 inhibitor is a humanized antibody. [A2.5] The pharmaceutical composition of any one of A2.1-A2.4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. [A2.6] The pharmaceutical composition of A2.5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2. [A2.7] The pharmaceutical composition of A2.5 or A2.6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4. [A2.8] The pharmaceutical composition of any one of A2.5-A2.7, wherein the IL-6 inhibitor is satralizumab. [A2.9] The pharmaceutical composition of any one of A2.1-A2.8, for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [A2.10] The pharmaceutical composition of any one of A2.1-A2.9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS). [A2.11] The pharmaceutical composition of any one of A2.1-A2.10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis. [A2.12] The pharmaceutical composition of any one of A2.1-A2.11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). [A2.13] The pharmaceutical composition of A2.12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [A2.14] The pharmaceutical composition of any one of A2.1-A2.13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [A2.15] The pharmaceutical composition of any one of A2.1-A2.14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative. [A2.16] The pharmaceutical composition of any one of A2.1-A2.15, wherein the subject is aged 12 years or older. [A2.17] The pharmaceutical composition of any one of A2.1-A2.16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy. [A2.18] The pharmaceutical composition of any one of A2.1-A2.16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS. [A2.19] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration. [A2.20] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [A2.21] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [A2.22] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [A2.23] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [A2.24] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [A2.25] The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [A2.26] The pharmaceutical composition of any one of A2.5-A2.25, which is characterized in that the pharmaceutical composition is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously. [A2.27] The pharmaceutical composition of any one of A2.5-A2.26, which is characterized in that the pharmaceutical composition is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [A2.28] The pharmaceutical composition of any one of A2.1-A2.27, which is characterized in that the pharmaceutical composition is used in combination with an immunosuppressive therapy (IST). [A2.29] The pharmaceutical composition of A2.28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and oral corticosteroid (OCS). [A2.30] The pharmaceutical composition of A2.29, wherein the immunosuppressive agent comprises prednisone or prednisolone. [A2.31] The pharmaceutical composition of any one of A2.1-A2.30, which delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [A2.32] The pharmaceutical composition of A2.31, which reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations. [A2.33] The pharmaceutical composition of any one of A2.1-A2.32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers. [B1] Use of an IL-6 inhibitor in the preparation of a medicament for treating demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody or for reducing risk of relapse in a relapsing demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody in a subject who is anti-MOG antibody-positive. [B2] The use of B1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof. [B3] The use of B1 or B2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof. [B4] The use of any one of B1-B3, wherein the IL-6 inhibitor is a humanized antibody. [B5] The use of any one of B1-B4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. [B6] The use of B5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2. [B7] The use of B5 or B6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4. [B8] The use of any one of B5-B7, wherein the IL-6 inhibitor is satralizumab. [B9] The use of any one of B1-B8, wherein the medicament is for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [B10] The use of any one of B1-B9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS). [B11] The use of any one of B1-B10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis. [B12] The use of any one of B1-B11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). [B13] The use of B12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [B14] The use of any one of B1-B13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [B15] The use of any one of B1-B14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative. [B16] The use of any one of B1-B15, wherein the subject is aged 12 years or older. [B17] The use of any one of B1-B16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy. [B18] The use of any one of B1-B16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS. [B19] The use of any one of B5-B18, wherein the medicament is characterized in that the medicament is used such that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration. [B20] The use of any one of B5-B18, which is characterized in that the medicament is used such that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [B21] The use of any one of B5-B18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [B22] The use of any one of B5-B18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [B23] The use of any one of B5-B18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [B24] The use of any one of B5-B18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [B25] The use of any one of B5-B18, which is characterized in that the medicament is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [B26] The use of any one of B5-B25, wherein the medicament is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously. [B27] The use of any one of B5-B26, wherein the medicament is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [B28] The use of any one of B1-B27, wherein the medicament is characterized in that the medicament is used in combination with an immunosuppressive therapy (IST). [B29] The use of B28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF), and oral corticosteroid (OCS). [B30] The use of B29, wherein the immunosuppressive agent comprises prednisone or prednisolone. [B31] The use of any one of B1-B30, wherein the medicament delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [B32] The use of B31, wherein the medicament reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations. [B33] The use of any one of B1-B32, wherein the medicament increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers. [C1] An IL-6 inhibitor for use in treating a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, or for use in reducing risk of relapse in a relapsing demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody in a subject who is anti-MOG antibody-positive. [C2] The IL-6 inhibitor for use of C1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof. [C3] The IL-6 inhibitor of C1 or C2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof. [C4] The IL-6 inhibitor of any one of C1-C3, wherein the IL-6 inhibitor is a humanized antibody. [C5] The IL-6 inhibitor of any one of C1-C4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. [C6] The IL-6 inhibitor for use of C5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2. [C7] The IL-6 inhibitor for use of C5 or C6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4. [C8] The IL-6 inhibitor for use of any one of C5-C7, wherein the IL-6 inhibitor is satralizumab. [C9] The IL-6 inhibitor for use of any one of C1-C8, for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [C10] The IL-6 inhibitor for use of any one of C1-C9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS). [C11] The IL-6 inhibitor for use of any one of C1-C10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis. [C12] The IL-6 inhibitor for use of any one of C1-C11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). [C13] The IL-6 inhibitor for use of C12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [C14] The IL-6 inhibitor for use of any one of C1-C13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination. [C15] The IL-6 inhibitor for use of any one of C1-C14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative. [C16] The IL-6 inhibitor for use of any one of C1-C15, wherein the subject is aged 12 years or older. [C17] The IL-6 inhibitor for use of any one of C1-C16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy. [C18] The IL-6 inhibitor for use of any one of C1-C16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS. [C19] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration. [C20] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [C21] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration. [C22] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [C23] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration. [C24] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [C25] The IL-6 inhibitor for use of any one of C5-C18, which is characterized in that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration. [C26] The IL-6 inhibitor for use of any one of C5-C25, which is characterized in that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously. [C27] The IL-6 inhibitor for use of any one of C5-C26, which is characterized in that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C28] The IL-6 inhibitor for use of any one of C1-C27, which is used in combination with an immunosuppressive therapy (IST). [C29] The IL-6 inhibitor for use of C28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and oral corticosteroid (OCS). [C30] The IL-6 inhibitor for use of C29, wherein the immunosuppressive agent comprises prednisone or prednisolone. [C31] The IL-6 inhibitor for use of any one of C1-C30, which delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody. [C32] The IL-6 inhibitor for use of C31, which reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations. [C33] The IL-6 inhibitor for use of any one of C1-C32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers. [C34] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON). [C35] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM). [C36] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination. [C37] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination. [C38] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM). [C39] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C40] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C41] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C42] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C43] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C44] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C45] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C46] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C47] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C48] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C49] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON). [C50] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM). [C51] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination. [C52] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination. [C53] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM). [C54] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C55] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C56] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C57] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C58] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C59] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination. [C60] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C61] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C62] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C63] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination. [C64] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C65] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C66] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C67] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C68] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C69] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C70] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C71] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C72] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C73] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C74] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C75] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C76] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C77] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C78] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C79] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C80] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C81] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C82] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C83] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C84] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C85] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C86] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C87] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C88] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C89] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C90] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C91] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C92] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C93] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C94] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C95] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C96] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C97] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C98] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C99] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C100] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C101] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C102] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C103] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C104] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C105] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C106] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C107] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C108] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C109] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C110] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C111] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C112] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C113] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C114] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C115] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C116] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C117] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C118] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C119] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C120] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C121] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C122] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C123] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C124] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C125] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C126] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C127] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C128] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C129] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C130] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C131] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C132] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C133] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C134] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C135] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C136] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C137] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C138] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C139] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C140] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C141] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C142] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C143] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C144] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C145] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C146] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C147] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C148] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C149] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C150] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C151] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C152] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C153] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C154] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C155] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C156] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C157] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C158] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C159] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C160] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C161] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C162] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C163] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C164] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C165] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C166] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C167] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C168] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C169] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C170] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C171] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C172] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C173] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C174] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C175] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C176] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C177] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C178] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C179] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C180] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C181] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C182] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C183] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C184] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C185] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C186] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C187] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C188] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C189] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C190] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C191] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C192] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C193] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C194] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C195] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C196] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C197] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C198] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C199] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C200] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C201] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C202] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C203] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C204] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C205] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C206] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C207] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C208] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C209] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C210] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C211] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C212] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C213] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C214] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C215] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C216] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C217] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C218] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C219] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C220] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C221] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C222] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C223] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C224] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C225] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C226] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C227] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C228] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C229] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C230] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C231] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C232] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C233] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C234] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C235] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C236] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C237] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C238] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C239] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C240] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C241] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C242] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C243] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W). [C244] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with azathioprine (AZA). [C245] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA). [C246] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C247] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C248] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA). [C249] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C250] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C251] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C252] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C253] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C254] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C255] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C256] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C257] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C258] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C259] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with azathioprine (AZA). [C260] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA). [C261] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C262] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C263] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA). [C264] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C265] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C266] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C267] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C268] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C269] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C270] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C271] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C272] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C273] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA). [C274] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C275] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C276] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C277] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C278] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C279] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C280] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C281] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C282] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C283] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C284] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C285] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C286] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C287] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C288] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C289] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C290] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C291] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C292] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C293] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C294] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C295] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C296] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C297] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C298] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C299] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C300] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C301] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C302] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C303] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C304] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C305] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C306] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C307] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C308] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C309] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C310] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C311] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C312] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C313] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C314] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C315] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C316] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C317] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C318] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C319] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C320] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C321] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C322] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C323] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C324] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C325] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C326] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C327] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C328] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C329] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C330] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C331] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C332] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C333] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C334] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C335] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C336] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C337] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C338] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C339] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C340] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C341] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C342] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C343] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C344] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C345] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C346] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C347] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C348] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C349] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C350] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C351] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C352] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C353] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C354] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C355] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C356] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C357] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C358] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C359] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C360] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C361] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C362] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C363] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C364] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C365] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C366] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C367] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C368] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C369] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C370] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C371] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C372] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C373] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C374] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C375] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C376] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C377] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C378] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C379] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C380] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C381] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C382] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C383] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C384] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C385] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C386] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C387] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C388] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C389] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C390] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C391] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C392] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C393] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C394] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C395] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C396] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C397] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C398] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C399] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C400] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C401] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C402] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C403] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C404] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C405] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C406] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C407] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C408] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C409] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C410] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C411] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C412] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C413] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C414] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C415] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C416] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C417] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C418] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C419] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C420] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C421] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C422] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C423] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C424] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C425] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C426] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C427] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C428] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C429] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C430] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C431] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C432] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA). [C433] Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of bra...

Claims

1. A medicament for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), in a subject who is anti-MOG antibody-positive, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

2. The medicament of claim 1, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2.

3. The medicament of claim 1 or 2, wherein the anti-IL-6 receptor antibody is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.

4. The medicament of any one of claims 1-3, wherein the anti-IL-6 receptor antibody is satralizumab.

5. The medicament of any one of claims 1-4, for delaying relapse of, reducing frequency of relapse of, reducing severity of relapse of MOGAD, or reducing the risk of relapse in a patient with MOGAD.

6. The medicament of any one of claims 1-5, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay; and (ii) 2 or more attacks of any one or more of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.

7. The medicament of any one of claims 1-6, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative.

8. The medicament of any one of claims 1-7, which is characterized in that the medicament is used such that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively.

9. The medicament of any one of claims 1-8, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously.

10. The medicament of any one of claims 1-9, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).

11. The medicament of any one of claims 1-10, which is characterized in that the medicament is used in combination with an immunosuppressive therapy (IST).

12. The medicament of claim 11, wherein the IST is a therapy with one or more of immunosuppressive agent selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and oral corticosteroid (OCS).

13. The medicament of claim 12, wherein the immunosuppressive agent comprises prednisone or prednisolone.

14. A subcutaneous administration device comprising a fixed dose of 60 mg of satralizumab in a pharmaceutically acceptable excipient.

15. A subcutaneous administration device comprising a fixed dose of 240 mg of satralizumab in a pharmaceutically acceptable excipient.

Images